Open
The DHA’s submission supports repealing the Therapeutic Products Act, arguing its broad SaMD regulation stifles innovation, increases costs, and limits digital health progress. CEO Ryl Jensen urges agile, risk-proportionate legislation that ensures safety while supporting industry growth and efficiency.